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AML patients are reported to have impairments of
immune cells which contribute to leukemia progression.
Tumor-derived exosomes (TEX) have recently emerged
as carriers of the molecular and genetic cargo with
potent immunosuppressive properties. We showed that
plasma of newly-diagnosed AML patients prior to any
therapy contained high levels of exosomal proteins rela-
tive to those in plasma of normal donors (NC). AML
exosomes were enriched in membrane-associated
TGF-b1, MICA/MICB and markers of myeloid blasts.
We hypothesize that these plasma-derived virus-size
(30-100nm) membrane-bound vesicles operating in
AML deliver suppressive signals to immune cells and
thus may promote leukemia progression.
Methods
Venous blood (20-50 mL) was obtained from patients
newly diagnosed with AML prior to any treatment, from
AML patients who achieved CR following initial therapy
and from age-matched NC. Exosome fractions were iso-
lated from plasma using mini-size exclusion chromato-
graphy (mini-SEC) with Sepharose 2A. Exosome protein
levels, numbers and size of exosomes (qNano) and their
morphology (TEM) were determined. Exosomes were
characterized by Western blots for expression of exosome
markers, Tsg101 and CD81, and myeloid cell-surface
markers associated with AML, interleukin-3 receptor
alpha chain (CD123) and C-type lectin-like molecule-1
(CLL-1), CD44 and CD96. Isolated normal human NK
cells were co-incubated with AML exosomes and multi-
parameter flow cytometry was used to monitor changes
in expression levels of NKG2D on NK cells.
Results
Exosome fractions isolated from AML patients’ plasma
at diagnosis (n=16) had higher mean protein content
than fractions obtained from NC plasma (96 vs 37 µg
protein/mL plasma, p=0.03). Exosomes were isolated
from paired AML plasma samples obtained at diagnosis
and in CR after chemotherapy (n=13). In the exosome
fractions isolated at CR, at the time when leukemic
blasts were undetectable in the bone marrow by conven-
tional hematopathological methods, protein levels
remained elevated (mean value=120 µg protein/mL
plasma). AML exosomes isolated at CR carried blast
markers, CD123, CLL-1, CD44, CD96 and were
enriched in the mature form of TGF-b1. Co-incubation
of these exosomes with activated normal human NK
cells resulted in down-regulation of NKG2D expression
with a concomitant reduction of NK-cell cytotoxicity.
Ten/13 AML patients in CR whose plasma exosome
levels remained elevated eventually relapsed.
Conclusion
The exosome fractions in plasma of patients with AML
are enriched in blast-derived exosomes carrying leukemia
blast markers and biologically-active TGF-b1. The persis-
tently elevated levels of these exosomes in plasma of AML
patients in CR contribute to impaired anti-leukemia
immune responses and promote leukemia progression.
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